Esen Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 15-12-2024
- Paid Up Capital ₹ 0.50 M
as on 15-12-2024
- Company Age 11 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.60 M
as on 15-12-2024
- Revenue %
(FY 2020)
- Profit -291.17%
(FY 2020)
- Ebitda -481.99%
(FY 2020)
- Net Worth -272.76%
(FY 2020)
- Total Assets 72.47%
(FY 2020)
About Esen Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹6.60 M.
Lim Lin, Rajesh Savera, and Debya Prakash serve as directors at the Company.
- CIN/LLPIN
U24100PY2013PTC008466
- Company No.
008466
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Mar 2013
- Date of AGM
24 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pondicherry
Industry
Company Details
- Location
Pondicherry, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Esen Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Savera  | Director | 06-Nov-2020 | Current |
| Debya Prakash | Additional Director | 13-Nov-2024 | Current |
Lim Lin  | Director | 23-Aug-2018 | Current |
Financial Performance and Corporate Structure Insights of Esen Lifesciences.
Esen Lifesciences Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 291.17% decrease in profit. The company's net worth observed a substantial decline by a decrease of 272.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Esen Lifesciences?
In 2020, Esen Lifesciences had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
Dxn Manufacturing (India) Private LimitedActive 23 years 4 monthsLim Lin and Rajesh Savera are mutual person
- Dxn Clinics Private LimitedActive 5 years 11 months
Lim Lin, Rajesh Savera and 1 more are mutual person
- Pine Biotech Private LimitedActive 12 years 5 months
Rajesh Savera and Debya Prakash are mutual person
_PRIVATE_LIMITED.webp)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 29 Jan 2016 | ₹6.60 M | Open |
How Many Employees Work at Esen Lifesciences?
Esen Lifesciences has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Esen Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Esen Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
